Pfizer doubles down with its 2nd FDA hemophilia approval in 6 months

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pfizer has earned a nod from the U.S. regulator for another of its products in the indication.

On Friday, the FDA signed off on Hympavzi (marstacimab-hncq), an anti-tissue factor pathway inhibitor for patients age 12 and older with hemophilia A or B who have not developed antibodies to previous inhibitor treatments.